Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Sunpharma Ltd — Q1 FY25
Sun Pharma reported a solid Q1 FY25 with consolidated sales of INR 12,524.5 crore (+6.3% YoY) and EBITDA margin expansion of 60 bps to 28.5%.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Sun Pharma reported a solid Q1 FY25 with consolidated sales of INR 12,524.5 crore (+6.3% YoY) and EBITDA margin expansion of 60 bps to 28.5%. PAT surged 40.2% YoY to INR 2,835.6 crore, aided by lower base and operational leverage. India formulation grew 16.4% YoY to INR 4,144.5 crore, gaining market share to 8.6%. U.S. sales were flat at $466M, with specialty up 14.7% to $266M, driven by Ilumya and other products. Key highlight was FDA approval of Leqselvi for alopecia areata, though a preliminary injunction motion by Incyte may delay launch. Management guided for higher R&D spend in subsequent quarters (8-10% of sales) and expects tax rate to normalize. Risk: Leqselvi launch uncertainty due to litigation could impact near-term specialty growth.
सन फार्मा ने पहली तिमाही (अप्रैल-जून 2024) में अच्छा प्रदर्शन किया। कंपनी की कुल बिक्री 12,524.5 करोड़ रुपये रही, जो पिछले साल से 6.3% ज्यादा है। कमाई बढ़ाने की क्षमता (EBITDA मार्जिन) 28.5% हो गई, जो पिछली बार से 0.60% अधिक है। मुनाफा (PAT) 40.2% बढ़कर 2,835.6 करोड़ रुपये हो गया, क्योंकि पिछले साल का आधार कम था और खर्चों पर नियंत्रण रहा। भारत में दवाओं की बिक्री 16.4% बढ़कर 4,144.5 करोड़ रुपये हुई, और बाजार हिस्सेदारी 8.6% पहुंच गई। अमेरिका में बिक्री 466 मिलियन डॉलर पर स्थिर रही, लेकिन खास दवाओं (स्पेशियलिटी) की बिक्री 14.7% बढ़ी। खास बात यह है कि गंजापन (एलोपेसिया एरीटा) की दवा लेक्सेल्वी को FDA ने मंजूरी दी, लेकिन इनसाइट कंपनी के मुकदमे के कारण इसकी बिक्री शुरू करने में देरी हो सकती है। आगे कंपनी रिसर्च पर ज्यादा खर्च करेगी (बिक्री का 8-10%) और टैक्स दर सामान्य होने की उम्मीद है। जोखिम: मुकदमे के कारण लेक्सेल्वी की बिक्री पर
Promises0 met · 2 missedRisks3 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
3 risks
Risk Intelligence
Leqselvi launch delay due to litigation
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India Market Share
8.6%
+30bps YoY
Sun Pharma gained 30 bps market share in the Indian pharma market (MAT June 2024), now at 8.6%.
Global Specialty Sales
$266M
+14.7% YoY
Global specialty sales grew 14.7% YoY to $266M, driven by Ilumya and other products.
U.S. Generic Launches
5
flat YoY
Launched 5 generic products in the U.S. during Q1, consistent with prior year.
India New Product Launches
6
flat YoY
Launched 6 new products in India during Q1, maintaining launch cadence.
What Changed vs Last Quarter
NEW
Effective tax rate to increase on full-year basis
Tax rate expected to rise due to expiry of certain exemptions; should be viewed on an annualized basis.
NEW
Leqselvi launch pending court decision on preliminary injunction
Launch timing of Leqselvi will be governed by court ruling on Incyte's motion; company opposes and seeks early outcome.
UPDATED
R&D spend to step up to 8-10% of sales for FY25
Management expects R&D investment to increase in subsequent quarters, with full-year guidance of 8-10% of sales.
DROPPED
High single-digit consolidated revenue growth for FY25
Management expects consolidated top-line growth in high single digits for FY2025, driven by all business segments.
DROPPED
Deuruxolitinib launch post-PDUFA date (July 2024)
Deuruxolitinib is on track for launch after the July 2024 PDUFA date, with pre-launch costs already being incurred.
NEW RISK
Leqselvi launch delay due to litigation
Incyte filed a preliminary injunction motion to block Leqselvi launch; outcome uncertain and could delay revenue contribution.
NEW RISK
Halol plant re-audit timeline uncertain
Management plans to request FDA re-audit once ready, but no specific timeline provided; pending approvals may impact U.S. generic pipeline.
NEW RISK
U.S. generic revenue flat despite Revlimid contribution
U.S. generic sales were flat sequentially; Revlimid contribution was not large this quarter, and sustainability is uncertain.
RISK GONE
FDA compliance issues at Mohali and Dadra plants
OAI status and 483 observations at Mohali and Dadra facilities could impact US generic launches and revenue.
RISK GONE
Elevated R&D and launch costs pressuring margins
Higher R&D spend (8-10% of sales) and deuruxolitinib launch costs may compress EBITDA margins in FY25.
RISK GONE
Pricing pressure from Stelara biosimilars
Stelara biosimilar entry next year could impact Ilumya pricing and market share in the US psoriasis market.
RISK GONE
Currency depreciation in emerging markets
Nigeria forex loss and broader emerging market currency volatility could impact reported revenue and profitability.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
Management aims to grow India formulation business faster than the Indian pharmaceutical market on an annualized basis.
Mentioned in Q1 FY24, Q3 FY24
Supplies from Mohali plant are not normal; issues with product prioritization and quality clearances are causing delays.
Mentioned in Q2 FY24, Q4 FY24
Stelara biosimilar entry next year could impact Ilumya pricing and market share in the US psoriasis market.
Fast read
Guidance and risk preview
Management expects R&D investment to increase in subsequent quarters, with full-year guidance of 8-10% of sales.
Incyte filed a preliminary injunction motion to block Leqselvi launch; outcome uncertain and could delay revenue contribution.
View Risks →